A daily dose of aspirin led to a significant reduction in liver fat in patients with metabolic dysfunction–associated steatotic liver disease, according to new research.
Researchers conducted a six-month randomized trial comparing 81 mg of aspirin with a placebo in patients from a Boston hospital (JAMA 2024;331[11]:920-929). The patients in the trial were a mean age of 48 years, were mostly women (55%) and were diagnosed with MASLD without cirrhosis.
Compared with placebo, aspirin treatment